# US 2021/0343364 A1 · Methods and related aspects for quantitative ratiometric regression polymerase chain reaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0343364 A1
- Document ID: US20210343364A1
- Status: Published application
- Kind: A1
- Application number: 17/238,872
- Filed: 2021-04-23
- Published: 2021-11-04
- Earliest claimed: 2020-04-24
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Tza-Huei Jeff Wang; Alexander Y. Trick
- Web page: https://patentgrep.com/patent/US20210343364A1

## CPC

- C12Q 1/6895: for plants, fungi or algae
- C12Q 1/6851: Quantitative amplification
- C12Q 1/686: Polymerase chain reaction [PCR]
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 25/20: Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/13: Plant traits
- C12Q 2600/156: Polymorphic or mutational markers
- G16H 20/00: ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein are methods of performing multiplexed real-time quantitative ratiometric regression PCR (qRR-PCR) to determine the fractional abundance of target variants in a population. Related systems and computer program products are also provided.

## Claims

### Claim 1

A method of determining a fractional abundance of at least one target variant in a population at least partially using a computer, the method comprising:
amplifying at least a first target nucleic acid and at least a first reference nucleic acid together in a reaction mixture to produce amplification data that comprises one or more detectable signal levels detected as the first target nucleic acid and the first reference nucleic acid are amplified;
determining, by the computer, a ratio of the detectable signal levels detected for the first target nucleic acid to the detectable signal levels detected for the first reference nucleic acid to produce at least a first set of relative detectable signal level ratios;
determining, by the computer, a ratio of the detectable signal levels detected for the first target nucleic acid to a cumulative total of the detectable signal levels detected for the first target nucleic acid and for the first reference nucleic acid to produce at least a first set of cumulative detectable signal level ratios; and,
determining, by the computer, a fractional abundance of the first target variant in the population at and/or after the quantitation cycle (Cq) value for the first target nucleic acid from the first set of relative detectable signal level ratios and/or the first set of cumulative detectable signal level ratios and at least one N-dimensional standard curve generated from calibration data of known fractional abundance, where N is a number of ratios at different cycle numbers, thereby determining the fractional abundance of the target variant in the population.

### Claim 2 (depends on 1)

The method of claim 1, comprising determining the cumulative detectable signal ratio at a given amplification cycle using equation (1A):
DS
ratio
=
DS
1
⁢
stTNA
DS
1
⁢
stTNA
+
DS
1
⁢
stRNA
(
1
⁢
A
)
where DSratio is the cumulative detectable signal ratio at the given amplification cycle, DS1st TNA is a baseline substracted detectable signal value detected for the first target nucleic acid at the given amplification cycle, and DS1st RNA is a baseline substracted detectable signal value detected for the first reference nucleic acid at the given amplification cycle.

### Claim 3 (depends on 1)

The method of claim 1, comprising performing univariate logistic regression by fitting a fractional abundance value to a cumulative detectable signal ratio for a given amplification cycle to produce at least one univariate fit using equation (2A):
FA
=
a
1
+
b
*
c
-
(
R
⁡
(
x
)
-
d
)
+
e
(
2
⁢
A
)
where FA is the predicted FA, R is the cumulative detectable signal ratio at the given cycle, x, and a, b, c, d, and, e are constants.

### Claim 4 (depends on 3)

The method of claim 3, comprising performing bivariate weighted regression by fitting one or more pairs of the univariate logistic regressions to the cumulative detectable signal ratios with parabolic weighting to produce at least one bivariate fit.

### Claim 5 (depends on 1)

The method of claim 1, comprising determining the ratio of the detectable signal levels detected for the first target nucleic acid to the detectable signal levels detected for the first reference nucleic acid at each of the amplification cycles to produce the first set of relative detectable signal level ratios.

### Claim 6 (depends on 1)

The method of claim 1, comprising determining the ratio of the detectable signal levels detected for the first target nucleic acid to the cumulative total of the detectable signal levels detected for the first target nucleic acid and for the first reference nucleic acid at each amplification cycle to produce the first set of cumulative detectable signal level ratios.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first target nucleic acid comprises at least a portion of at least one target genetic locus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the target genetic locus is associated with at least one disease, condition, or disorder.

### Claim 9 (depends on 1)

The method of claim 1, comprising obtaining the first target nucleic acid from a subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein the fractional abundance of the target variant in the population indicates that the subject has the disease, condition, or disorder.

### Claim 11 (depends on 1)

The method of claim 1, wherein the N-dimensional standard curve generated by:
amplifying at least a first target nucleic acid and at least a first reference nucleic acid together in a reaction mixture to produce amplification data that comprises one or more detectable signal levels detected as the first target nucleic acid and the first reference nucleic acid are amplified, wherein at least initial fractional abundances of the first target nucleic acid and the first reference nucleic acid in the reaction mixture are known;
subtracting, by the computer, at least one baseline detectable signal level value from the amplification data to produce baseline adjusted data;
determining, by the computer, one or more ratios from the baseline adjusted data at one or more amplification cycles to produce at least a first set of amplification ratios;
calculating, by the computer, adjusted cycle numbers for the first set of amplification ratios to produce at least a first set of adjusted amplification data;
fitting, by the computer, fractional abundance values to the first set of adjusted amplification data using at least one fitting technique to produce fractional abundance fits; and,
selecting, by the computer, a best fit for modeling fractional abundance from the fractional abundance fits.

### Claim 12 (depends on 1)

The method of claim 1, comprising determining a fractional abundance of more than one target variant in the population.

### Claim 13 (depends on 1)

The method of claim 1, comprising determining the ratio of the detectable signal level detected for the first target nucleic acid to the detectable signal level detected for the first reference nucleic acid after an elongation step of a given amplification cycle.

### Claim 14 (depends on 1)

The method of claim 1, wherein N comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more ratios at different cycle numbers.

### Claim 15

A method of generating a standard curve for determining a fractional abundance of at least one target variant in a population at least partially using a computer, the method comprising:
amplifying at least a first target nucleic acid and at least a first reference nucleic acid together in a reaction mixture to produce amplification data that comprises one or more detectable signal levels detected as the first target nucleic acid and the first reference nucleic acid are amplified, wherein at least initial fractional abundances of the first target nucleic acid and the first reference nucleic acid in the reaction mixture are known;
subtracting, by the computer, at least one baseline detectable signal level value from the amplification data to produce baseline adjusted data;
determining, by the computer, one or more ratios from the baseline adjusted data at one or more amplification cycles to produce at least a first set of amplification ratios;
calculating, by the computer, adjusted cycle numbers for the first set of amplification ratios to produce at least a first set of adjusted amplification data;
fitting, by the computer, fractional abundance values to the first set of adjusted amplification data using at least one fitting technique to produce fractional abundance fits; and,
selecting, by the computer, a best fit for modeling fractional abundance from the fractional abundance fits, thereby generating the standard curve for determining the fractional abundance of the target variant in the population.

### Claim 16 (depends on 15)

The method of claim 15, comprising selecting the best fit for modeling fractional abundance using a residual sum of squares (RSS) technique.

### Claim 17 (depends on 15)

The method of claim 15, comprising calculating the adjusted cycle numbers by subtracting a nearest integer value to a quantitation cycle (Cq) value for the first reference nucleic acid.

### Claim 18 (depends on 15)

The method of claim 15, comprising determining a quantitation cycle (Cq) value for the first target nucleic acid and/or the first reference nucleic acid from the amplification data.

### Claim 19 (depends on 15)

The method of claim 15, comprising determining the best fit for modeling fractional abundance by calculating a residual sum of squares (RSS) for the univariate and bivariate fits and selecting a model with a lowest RSS value.

### Claim 20 (depends on 15)

The method of claim 15, comprising identifying ratio values in the first set of adjusted amplification data that are at and/or after a quantitation cycle (Cq) value to produce at least a first set of selected reference Cq values.

### Claim 21 (depends on 15)

The method of claim 15, comprising subtracting a quantitation cycle (Cq) value for the first reference nucleic acid from the first set of amplification ratios to produce at least a first set of adjusted amplification data.

### Claim 22 (depends on 15)

The method of claim 15, comprising generating the standard curve for determining the fractional abundance of the target variant in the population using multiple different known initial fractional abundances of the first target nucleic acid and the first reference nucleic acid in the reaction mixture.

### Claim 23 (depends on 15)

The method of claim 15, wherein the initial fractional abundance of the first reference nucleic acid in the reaction mixture is about 5%.

### Claim 24 (depends on 15)

The method of claim 15, wherein the fitting technique comprises logistic regression and at least one weighting scheme.

### Claim 25 (depends on 24)

The method of claim 24, wherein the logistic regression comprises univariate or polynomial logistic regression.

### Claim 26 (depends on 24)

The method of claim 24, wherein the weighting scheme comprises parabolic weighted regression.

### Claim 27 (depends on 26)

The method of claim 26, wherein the parabolic weighted regression comprises multivariate parabolic weighted regression.

### Claim 28 (depends on 27)

The method of claim 27, wherein the multivariate parabolic weighted regression comprises bivariate parabolic weighted regression.

### Claim 29

A system, comprising a controller comprising, or capable of accessing, computer readable media comprising non-transitory computer-executable instructions which, when executed by at least one electronic processor perform at least:
determining a ratio of detectable signal levels detected for at least a first target nucleic acid to detectable signal levels detected for at least a first reference nucleic acid to produce at least a first set of relative detectable signal level ratios from amplification data that comprises one or more detectable signal levels detected as the first target nucleic acid and the first reference nucleic acid are amplified in a reaction mixture;
determining a ratio of the detectable signal levels detected for the first target nucleic acid to a cumulative total of the detectable signal levels detected for the first target nucleic acid and for the first reference nucleic acid to produce at least a first set of cumulative detectable signal level ratios; and,
determining a fractional abundance of at least a first target variant in a population at and/or after the quantitation cycle (Cq) value for the first target nucleic acid from the first set of relative detectable signal level ratios and/or the first set of cumulative detectable signal level ratios and at least one N-dimensional standard curve generated from calibration data of known fractional abundance, where Nis a number of ratios at different cycle numbers, to determine the fractional abundance of the target variant in the population.
